J. Ives

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients

Atul Humar, Y Lebranchu, Flavio Vincenti et al. · American Journal of Transplantation · 2010 · 499 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +17

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo

J. Ives, Jackie Carr, Dirk B. Mendel et al. · Antiviral Research · 2002 · 382 citations

Life Sciences, Infectious Diseases, Molecular Biology +15

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

Jackie Carr, J. Ives, Lauren E. Kelly et al. · Antiviral Research · 2002 · 175 citations

Life Sciences, Infectious Diseases, Molecular Virology +13

Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets

M. Louise Herlocher, Jackie Carr, J. Ives et al. · Antiviral Research · 2002 · 156 citations

Life Sciences, Infectious Diseases, Microbiology +11

Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients

W Vaudrya, R Ettengerb, P Jarac et al. · American Journal of Transplantation · 2009 · 122 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17